Intensification of preoperative chemotherapy for osteogenic sarcoma

Results of the Memorial Sloan-Kettering (T12) protocol

Paul A. Meyers, Richard Gorlick, Glenn Heller, Ephraim Casper, Joseph Lane, Andrew G. Huvos, John H. Healey

Research output: Contribution to journalArticle

243 Citations (Scopus)

Abstract

Purpose: It has been observed previously in osteosarcoma (OS) that the degree of necrosis of the resected primary tumor following a period of preoperative chemotherapy is predictive of subsequent event-free survival (EFS). The aim of this study was to determine if more intensive preoperative chemotherapy would increase the proportion of patients with a good histologic response and improve EFS. Patients and Methods: Seventy-three patients with OS were treated at Memorial-Sloan Kettering Cancer Center (MSKCC) on the T12 protocol between 1986 and 1993. Patients were randomized between therapy based on the T10 protocol and therapy with more intensive preoperative chemotherapy. The more intensive preoperative regimen consisted of two courses of cisplatin (CDDP) and doxorubicin (DOX) in addition to the usual preoperative regimen of high-dose methotrexate (HD MTX) and bleomycin, cyclophosphamide, and dactinomycin (BCD). Results: The regimen with more intensive preoperative chemotherapy achieved a modest increase in the proportion of patients with a good histologic response (44% with a grade III or IV histologic response v 37% in the control arm, 33% with grade IV histologic response v 13% in the control arm). EFS continued to correlate with histologic response. The actuarial 5-year EFS in patients with localized disease was 78% for the regimen with more intensive preoperative chemotherapy and 73% for the control arm. Conclusion: Despite modest increases in the proportion of patients with good histologic response with intensified preoperative chemotherapy, no improvement in EFS was observed.

Original languageEnglish (US)
Pages (from-to)2452-2458
Number of pages7
JournalJournal of Clinical Oncology
Volume16
Issue number7
StatePublished - Jul 1998
Externally publishedYes

Fingerprint

Osteosarcoma
Disease-Free Survival
Drug Therapy
Preoperative Period
Bleomycin
Dactinomycin
Methotrexate
Doxorubicin
Cyclophosphamide
Cisplatin
Neoplasms
Necrosis
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H. (1998). Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) protocol. Journal of Clinical Oncology, 16(7), 2452-2458.

Intensification of preoperative chemotherapy for osteogenic sarcoma : Results of the Memorial Sloan-Kettering (T12) protocol. / Meyers, Paul A.; Gorlick, Richard; Heller, Glenn; Casper, Ephraim; Lane, Joseph; Huvos, Andrew G.; Healey, John H.

In: Journal of Clinical Oncology, Vol. 16, No. 7, 07.1998, p. 2452-2458.

Research output: Contribution to journalArticle

Meyers, PA, Gorlick, R, Heller, G, Casper, E, Lane, J, Huvos, AG & Healey, JH 1998, 'Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) protocol', Journal of Clinical Oncology, vol. 16, no. 7, pp. 2452-2458.
Meyers, Paul A. ; Gorlick, Richard ; Heller, Glenn ; Casper, Ephraim ; Lane, Joseph ; Huvos, Andrew G. ; Healey, John H. / Intensification of preoperative chemotherapy for osteogenic sarcoma : Results of the Memorial Sloan-Kettering (T12) protocol. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 7. pp. 2452-2458.
@article{022876a300bd4934bd4f2434e5a66b3d,
title = "Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) protocol",
abstract = "Purpose: It has been observed previously in osteosarcoma (OS) that the degree of necrosis of the resected primary tumor following a period of preoperative chemotherapy is predictive of subsequent event-free survival (EFS). The aim of this study was to determine if more intensive preoperative chemotherapy would increase the proportion of patients with a good histologic response and improve EFS. Patients and Methods: Seventy-three patients with OS were treated at Memorial-Sloan Kettering Cancer Center (MSKCC) on the T12 protocol between 1986 and 1993. Patients were randomized between therapy based on the T10 protocol and therapy with more intensive preoperative chemotherapy. The more intensive preoperative regimen consisted of two courses of cisplatin (CDDP) and doxorubicin (DOX) in addition to the usual preoperative regimen of high-dose methotrexate (HD MTX) and bleomycin, cyclophosphamide, and dactinomycin (BCD). Results: The regimen with more intensive preoperative chemotherapy achieved a modest increase in the proportion of patients with a good histologic response (44{\%} with a grade III or IV histologic response v 37{\%} in the control arm, 33{\%} with grade IV histologic response v 13{\%} in the control arm). EFS continued to correlate with histologic response. The actuarial 5-year EFS in patients with localized disease was 78{\%} for the regimen with more intensive preoperative chemotherapy and 73{\%} for the control arm. Conclusion: Despite modest increases in the proportion of patients with good histologic response with intensified preoperative chemotherapy, no improvement in EFS was observed.",
author = "Meyers, {Paul A.} and Richard Gorlick and Glenn Heller and Ephraim Casper and Joseph Lane and Huvos, {Andrew G.} and Healey, {John H.}",
year = "1998",
month = "7",
language = "English (US)",
volume = "16",
pages = "2452--2458",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Intensification of preoperative chemotherapy for osteogenic sarcoma

T2 - Results of the Memorial Sloan-Kettering (T12) protocol

AU - Meyers, Paul A.

AU - Gorlick, Richard

AU - Heller, Glenn

AU - Casper, Ephraim

AU - Lane, Joseph

AU - Huvos, Andrew G.

AU - Healey, John H.

PY - 1998/7

Y1 - 1998/7

N2 - Purpose: It has been observed previously in osteosarcoma (OS) that the degree of necrosis of the resected primary tumor following a period of preoperative chemotherapy is predictive of subsequent event-free survival (EFS). The aim of this study was to determine if more intensive preoperative chemotherapy would increase the proportion of patients with a good histologic response and improve EFS. Patients and Methods: Seventy-three patients with OS were treated at Memorial-Sloan Kettering Cancer Center (MSKCC) on the T12 protocol between 1986 and 1993. Patients were randomized between therapy based on the T10 protocol and therapy with more intensive preoperative chemotherapy. The more intensive preoperative regimen consisted of two courses of cisplatin (CDDP) and doxorubicin (DOX) in addition to the usual preoperative regimen of high-dose methotrexate (HD MTX) and bleomycin, cyclophosphamide, and dactinomycin (BCD). Results: The regimen with more intensive preoperative chemotherapy achieved a modest increase in the proportion of patients with a good histologic response (44% with a grade III or IV histologic response v 37% in the control arm, 33% with grade IV histologic response v 13% in the control arm). EFS continued to correlate with histologic response. The actuarial 5-year EFS in patients with localized disease was 78% for the regimen with more intensive preoperative chemotherapy and 73% for the control arm. Conclusion: Despite modest increases in the proportion of patients with good histologic response with intensified preoperative chemotherapy, no improvement in EFS was observed.

AB - Purpose: It has been observed previously in osteosarcoma (OS) that the degree of necrosis of the resected primary tumor following a period of preoperative chemotherapy is predictive of subsequent event-free survival (EFS). The aim of this study was to determine if more intensive preoperative chemotherapy would increase the proportion of patients with a good histologic response and improve EFS. Patients and Methods: Seventy-three patients with OS were treated at Memorial-Sloan Kettering Cancer Center (MSKCC) on the T12 protocol between 1986 and 1993. Patients were randomized between therapy based on the T10 protocol and therapy with more intensive preoperative chemotherapy. The more intensive preoperative regimen consisted of two courses of cisplatin (CDDP) and doxorubicin (DOX) in addition to the usual preoperative regimen of high-dose methotrexate (HD MTX) and bleomycin, cyclophosphamide, and dactinomycin (BCD). Results: The regimen with more intensive preoperative chemotherapy achieved a modest increase in the proportion of patients with a good histologic response (44% with a grade III or IV histologic response v 37% in the control arm, 33% with grade IV histologic response v 13% in the control arm). EFS continued to correlate with histologic response. The actuarial 5-year EFS in patients with localized disease was 78% for the regimen with more intensive preoperative chemotherapy and 73% for the control arm. Conclusion: Despite modest increases in the proportion of patients with good histologic response with intensified preoperative chemotherapy, no improvement in EFS was observed.

UR - http://www.scopus.com/inward/record.url?scp=0031861214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031861214&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 2452

EP - 2458

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -